ArticleNPJ science of food2026
Sarcandra glabra alleviates intestinal injury via modulating gut microbiota and suppressing the IL-6/SOCS3 signaling pathway.
Article in NPJ science of food, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Research progress on intestinal probiotics-mediated protection of the intestinal mucosal barrier in ulcerative colitis.Frontiers in immunology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
Ulcerative colitis (UC) is a refractory inflammatory bowel disease characterized by gut microbiota dysbiosis and mucosal barrier disruption. Sarcandra glabra (Sg), a traditional herbal tea and dietary supplement, has been widely used to alleviate intestinal inflammation; however, its gut microbiota-dependent mechanism remains insufficiently clarified. In this study, Sg at 2, 4, and 8 g/kg was found to dose-dependently mitigate dextran sulfate sodium (DSS)-induced colitis in mice, restore mucosal barrier integrity by upregulating tight junction proteins and enhancing mucin secretion, and reduce serum levels of IL-1β, TNF-α, and IL-6. Integrative analysis of full-length 16S rRNA gene sequencing, transcriptomics, and metabolomics data revealed that Sg reshaped gut microbiota, selectively enriching Ligilactobacillus animalis while depleting Escherichia coli and Proteus vulgaris. We identified 8 microbiota-derived metabolites correlated with Ligilactobacillus animalis abundance, among which 2,3-dihydroxybenzoic acid (2,3-DHBA) exhibited the strongest protective effect against DSS-induced NCM460 cell damage. Mechanistic studies indicated that 2,3-DHBA effectively inhibited the IL-6/SOCS3 pathway and restored tight junction protein expression, effects that were reversed by exogenous IL-6. These findings demonstrate that Sg enriches for Ligilactobacillus animalis and its metabolite 2,3-DHBA, which suppresses IL-6-driven inflammation and repairs mucosal damage, supporting its potential as a microbiome-targeted dietary adjunct for UC.
Identifiers
42386748What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.